Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials

Climb Bio, Inc.

2025-Q3 EPS reported -$0.63

Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.
R&D expenses $9.1M (Q3 2025) vs $6.2M (Q3 2024); G&A $5.8M vs $5.5M.
Phase 2 PrisMN trial of budoprutug initiated; dosing expected in coming weeks.
CLYM116 Phase 1 trial cleared; first subject dosing expected by year-end 2025.
New leadership: CFO Susan Altschuller, SVP Tech Ops Adam Villa, SVP People Ashley Jones.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.